StockNews.AI
BMY
CNBC
33 days

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

1. BMY and Pfizer sell Eliquis directly, cutting prices over 40%. 2. New pricing aims to reduce patient out-of-pocket costs significantly. 3. Eliquis still costs more than Medicare negotiated prices set for next year. 4. Effort targets uninsured and self-pay patients, bypassing traditional middlemen. 5. Analyst predicts no major pricing headwinds for BMY from this initiative.

4m saved
Insight
Article

FAQ

Why Bullish?

Direct sales can enhance revenue and market access, similar to past direct-to-consumer strategies. Historical examples include companies boosting profits through enhanced patient access models.

How important is it?

Directly affects revenue and market positioning of Eliquis, crucial for BMY's performance as it represents a significant share of their income.

Why Short Term?

Immediate effects on revenue expected as discounts attract new patients. Long-term impacts will depend on overall market dynamics and governmental policies.

Related Companies

Related News